Background: Clinical study sites often do not achieve anticipated accrual to clinical trials, wasting critical patient, material, and human resources. The expensive and extensive process to bring a drug to approval highlights the need to streamline clinical pipeline processes. We sought to create a predictive accrual model to be used when considering clinical trial activation at the level of the individual site. Materials and Methods: This retrospective cohort study used 7 years of registry data from treatment and supportive care interventional studies at a single academic cancer center to build a negative binomial regression model with local and protocol variables known prestudy. Actual, team-predicted, and model-predicted accrual and sensitivity/specificity were calculated. Results: To build the model, 207 trials were used. Investigational drug application, disease team, number of national sites, local Institutional Review Board use, total national accrual time, accrual completed, and national enrollment goal were independently and significantly associated with accrual. Predicted accrual was 94% of actual, maintaining predictive value at multiple cutoff values. Validation included 61 trials. The model correctly predicted whether a study would accrue at least 4 subjects 75% of the time. Correlation at the category level was 44.3%, and model sensitivity and specificity are 70% and 78%, respectively. Conclusions: We identified and validated national and local key factors associated with accrual at our site. This methodology has not been previously validated broadly with the intent of trial feasibility. Model validation shows it to be an accurate and quick metric in anticipating accrual success that can be used for resource allocation.
Background
To draw scientifically sound conclusions, clinical trials must be completed in a timely manner and meet accrual goals. Forty-one percent of study chairs and lead statisticians surveyed "indicated that their trial experienced significant accrual difficulties." 1 Several studies found that 22% to 70% of clinical trials do not meet accrual goals. [2] [3] [4] [5] At the center level, 20% to 40% of studies do not accrue anyone. 6, 7 Up to 90% of clinical trials must extend the enrollment period. 8 An analysis of more than 24,000 protocols showed that, between 1989 and 2011, the number of Consequently, valuable scientific questions go unanswered. Methodologies are needed to choose trials that maximize accrual while minimizing economic and workforce burden.
Currently, no validated models exist assessing whether a proposed trial, when opened at a particular site, will accrue adequate subjects required to meet center-specific needs. We hypothesize that preexisting information regarding clinical trials can be used to generate a model predicting the likely overall center trial accrual before study activation.
Materials and Methods

Search Schema
This study was conducted at the University of Arizona Cancer Center (UACC), an NCI-designated comprehensive cancer center. Because there is no information about living individuals, this project does not meet the definition of human subject research, and therefore Institutional Review Board (IRB) approval was not required.
Studies were eligible for inclusion if they were therapeutic or supportive care, interventional protocols (defined by the NCI Data Table Guide) open at the UACC and whose status moved to "closed to accrual" between January 1, 2008, and October 18, 2013. All studies were associated with a disease team (DMG [disease management group]) that included clinical investigators and research staff. Teams vet potential clinical trials, overseeing study activation, screening, recruitment, consent, and study maintenance.
Center-specific study demographics were abstracted from the local clinical trial management system (CTMS) and included protocol identifier, ClinicalTrials.gov identifier (NCT ID, primary key), disease team/DMG (categorical), center-specific (nonaffiliate) actual accrual (continuous), DMGpredicted accrual (continuous), use of local IRB (yes/ no), phase (categorical), cooperative group sponsor (yes/no), inclusion of pediatric subjects (yes/no), the date the study was opened to accrual locally (numerical), and the date the study closed to accrual locally (numerical). Only the primary DMG who oversaw the study was used.
Protocol-specific demographics were abstracted from ClincialTrials.gov, a United States federal government Web site that lists clinical trials contributing to an approval application with the FDA, trying to publish in an International Committee of Medical Journal Editors (ICMJE) journal, or by voluntary submission. Protocol-wide demographics included sponsor name, randomized design (yes/no), placebo/ clinical observation arm (yes/no), primary end point (safety/toxicity only, efficacy, or other/laboratory), national enrollment goal (continuous), number of participating sites (1-9, 10-49, 50-199, ≥200 sites, unknown), national study start date (numerical), and national primary end point completion date (numerical). Where possible, information abstracted from the CTMS was verified with data listed in ClinicalTrials.gov. During abstraction of the number of national sites from ClinicalTrials.gov, some centers were not consistently listed or were listed multiple times. Therefore, this variable was categorized to describe study size better. Inclusion of "unknown sites" is relevant for predictive purposes, because many studies do not indicate the number of sites planned. Because the national closed-to-enrollment date was unavailable, the national primary end point completion date was used as a proxy for the date that accrual closed nationally.
Variable Definitions and Manipulations
During the review period, the local IRB was used for clinical trials where UACC was the only study site (investigator-initiated trial), the national principal investigator was the local investigator (UA-led study), an NCI-sponsored cooperative group study not offered through the NCI's Central IRB (CIRB), or any industry-sponsored clinical trial that did not utilize the Western IRB (WIRB, Olympia, WA). Local investigators could choose to utilize the local IRB, even if the study was eligible for external oversight.
From the abstracted data points, derivative variables were created. These included whether the study accrued zero subjects (yes/no), the months of accrual completed (calculated as the number of days between the national and local open to accrual dates divided by 30.4), and the total enrollment period (calculated as the number of days between the national start date and the national date of expected primary end point completion divided by 30.4).
The distribution of each continuous variable was assessed for normality using histogram graph matrices to see which transformation fit the data closest to a normal distribution. All continuous variables required transformation, which was done prior to data analysis.
Statistical Analyses
Summary statistics (frequency, mean, and standard deviation) were calculated for each variable. Collinearity of independent variables was assessed using chi-square tests. The outcome of accrual was highly right-skewed count data, needing a Poisson distribution to account for the data's non-normal distribution. Because the expected frequency of the outcome is not rare, the negative binomial distribution, a modification of the Poisson, was chosen for univariate and multivariate analyses. Univariate analyses measuring the association of each independent variable to the dependent variable of actual accrual were performed using a significance level of 0.05, set a priori. Reduced models testing for association to test for effect modification were performed, using a threshold of modification set at 10% change in the beta coefficient. Interaction models were performed on reduced models found to have effect modification. Factors found to be significant in the univariate models and the effect modification models were combined to create the full model. Predicted accrual was calculated for each study using the full model and the Pearson correlation coefficient calculated.
<4 Versus ≥4 Accrual Analysis
Studies were classified as having a predicted accrual of fewer than 4 or at least 4 subjects. Significant differences between studies that accrued at least 4 subjects versus less than 4 were tested for each independent, categorical variable using a chi-square test with Fisher's exact for variables with cell values less than 5. Continuous variables were tested using a 2-sided t-test with unequal variance.
Validation Set
Clinical trials that closed to accrual between October 18, 2013, and January 9, 2015, with the criteria used to build the model (described earlier) were abstracted and predicted accrual calculated. Demographic characteristics were compiled and sensitivity and specificity calculated.
Computational Support
Data abstraction was completed in Excel 2007 in comma-delimited format. Statistical analysis was performed using STATA-IC 12 (STATA Corp, College Station, TX).
Results
Study Characteristics
The number of eligible studies was 207. Of these, 152 accrued at least 1 subject (73.4%; median 3; range 0-208). Approximately 27% of studies (n=55) accrued no subjects locally. Frequency and mean accrual for study demographic characteristics are listed in Table 1 . A total of 48% of studies accrued 86% of subjects ( Figure 1 ). Two studies accrued more than 100 subjects locally; both were phase II investigatorinitiated trials within one disease team. The regression model was run with and without these studies and found no differences in model fit or beta coef- ficients. Therefore, these studies were included. Demographic variables were compared to determine whether any variables differed between studies that accrued any subjects and those that did not. Statistically different variables were: disease team and national sites (Table 2) .
Univariate Analysis
Six variables were independently associated with UACC accrual: investigational new drug, DMG, number of national sites, use of local IRB, expected duration of accrual, and length of time the study was open before local activation. National enrollment became significant when used in a reduced model with the variable national sites. The variables total months of accrual, months of accrual already completed, and proposed national enrollment were moderately correlated (ρ=≈.4 for each paring). The variables cooperative group and local IRB were significantly associated in a Spearman correlation analysis (P<.001). No significant change in the beta coefficient for local IRB (the variable more associated with accrual) was observed when these 2 variables were assessed in a reduced model. Therefore, only local IRB use was included.
Full Regression Model
Variables found to be significant in the univariate analyses and national enrollment were used to generate the full multivariate negative binomial regression model. The full model had 19 degrees of freedom and a significantly better fit than the Poisson model (P<.001), confirming the nonrare nature of the data and non-normal distribution. Variables most affecting the outcome of accrual were national enrollment and number of national sites (Table 3) . The model predicted 94% of actual accrual (1,427 of 1,511) . At the study level, predicted and actual accrual were strongly correlated (P=.81). The median difference in number of patients accrued between predicted and actual accrual was -0.56 (μ=0.41±11.24, not significant). Studies were categorized as having accrual of <1, 1<4, 4<7, 7<10, 10<20, 20<50, or >50. Eighty studies (39%) were identified to the same category of predicted and actual accrual (Table 4) .
Disease Team Versus Model Prediction
At UACC, the disease teams estimate anticipated local accrual as part of the study activation process, which allowed for comparison of our statistical model with another accrual prediction method. Overall, the disease teams predicted accrual of 2,561 subjects to the 207 trials, which was 169% of actual. The correlation between actual accrual and the disease team prediction was 0.77. When studies were categorized as described earlier, 41 studies (20%) were placed in the same category of predicted accrual and actual accrual (data not shown). The model predicted accrual better than the disease team for 9 of 11 teams (Table 5) .
Studies That Accrued <4 Versus ≥4 Subjects
We used the model to estimate its impact on overall trial accrual and activation if a cutoff value of 4 was used as the sole criterion for study activation. In this analysis, 108 of the 207 (52%) studies would not have been opened, and 214 subjects (14.2% of total) would not have accrued. These trials averaged accrual of 2 subjects (±2.6). Twenty four (22.2%) studies accrued 4 or more subjects; 77.8% were correctly rejected. Independent variables that differed between studies that accrued at least 4 subjects and those that did not were: disease team (P=.012), phase (P<.001), and national sites (P=.002).
Model Validation
Sixty-one trials met inclusion criteria for validation. Total accrual was 373 subjects (mean, 6.1±17.2). Sixteen studies (26.2%) had zero accrual, and 23 studies (37.7%) accrued 88.7% of subjects. Modelpredicted accrual was 513 subjects (138% of actual) versus disease team-predicted accrual of 1,111 subjects (298% of actual). The model correctly predicted whether a study would or would not accrue at least 4 subjects 75% of the time. Twenty-seven 
Percent of Total Cutoff Value from Predicted Model
Studies Actual accrual Predicted % of actual studies (44.3%) correlated perfectly at the category level (Table 6 ). Model sensitivity was 70%; specificity 78%. In comparison, disease team sensitivity was 100%; specificity 10%. Disease teams correctly predicted whether a study would or would not accrue at least 4 subjects 39% of the time. The model predicted that 38 studies would accrue less than 4 subjects. Seventeen studies (44.7%) were not correctly categorized. Nine (60%) were incorrectly categorized as favorable to open (predicted 4+, <4 accrued) and 6 (40%) would have incorrectly not opened (predicted <4, 4+ accrued). The model correctly identified all zero-accruing studies (n=16) as studies that would not accrue at least 4 subjects. The total accrual of these studies was 49 subjects, or 13.1% of all accrual (mode=1; median=1; mean=1.8±2.6).
Discussion
Clinical trials that fail to accrue increase human, monetary, and time costs. Determination of study success before resources are dedicated would improve clinical research performance, increase returns for investigators and centers, and, most importantly, increase returns for patients, both in clinically relevant trial results that can be applied to practice and in clinical trial participation opportunities. Research has focused on assessing whether a clinical trial population is available. 10, 11 However, individual centers need tools to select successful trials for activation using objective measures, which is currently unavailable and relies on the subjective opinion of investigators. This project was undertaken to develop more objective methods for estimating accrual.
We identified 6 variables independently associated with clinical trial accrual at our center. Combined with national accrual goal, these variables created a statistically significant regression model that predicted accrual more accurately than the disease team in 9 of 11 cases. Variables that impacted accrual at our center were investigational new drug (IND; the presence of an IND on the protocol, regardless of IND holder), disease team, use of local IRB, number of national sites, national length of enrollment, how many months of enrollment occurred before site initiation, and total national accrual goal. The variable with the greatest impact on predicted accrual is number of national sites, represented by the most extreme beta coefficients. These coefficients represent each variable's impact on predicted accrual. Adding the coefficients together and exponentiation of the total calculates the overall predicted accrual. Exponentiation of an individual coefficient indicates its contribution to predicted accrual, holding all other variables constant.
Validation found that the model predicted 138% of actual accrual; not as close as the original data set, but closer than disease team predictions of 169% and 298% of actual (model and validation, respectively). The model correctly predicted accrual of at least 4 subjects 75% of the time, versus disease team accuracy of 39%. At the individual study level, predicted accrual correlated strongly with actual accrual (ρ=.81). Mean accrual predicted from the model more closely matched actual than the disease teams (Table 5) .
It is doubtful that the specific IRB used directly impacts accrual. Our analysis found that the variable "use of local IRB" acts as a proxy for sponsor type and investigator engagement, because the cohort of studies that used the local IRB included mostly adult cooperative group clinical trials and investigator-initiated clinical trials. All industry-sponsored studies, and most pediatric oncology trials, used an external IRB.
Two factors, disease team and number of national sites, were significantly different between studies that accrued subjects and those that accrued none (Table  2) . Because disease teams are critical in accrual (team members actively recruit and consent subjects), it is not surprising that this variable is significant in ascertaining which studies will accrue. Teams have varying levels of research interest and available patient populations. In addition, investigator seniority and expertise (which varies by team) can be a factor in choosing a trial that will succeed. Although a formal assessment of disease team member characteristics was not performed, qualitatively, teams that had a combination of seasoned and multiple clinician researchers (associate and full professors) had higher accrual rates. Regarding the difference seen with national sites, it is expected that studies with a smaller number of sites would accrue more subjects per site. These studies represent investigator-initiated studies in which the local investigator has designed the trial or participates in a small network of colleagues executing a clinical trial. The investment in these trials is greater, leading to higher site-level accrual.
The value used for the dichotomous cutoff was set at 4 for this project. This value was selected based on the general function of the clinical trials unit at the institution under study, and was used for illustrative purposes. The accrual model yields a numerical accrual estimate, and therefore can accommodate any particular cutoff value selected.
Factors other than anticipated accrual come are considered when determining whether to activate a given clinical trial. These might include scientific merit, the patient profile served by an institution, and availability of staff resources. In the setting of rare diseases or pediatric studies, lower accrual than 4 patients per study may be justifiable. In other circumstances, accrual greater than 4 patients may be needed to justify activation. Irrespective of what values are selected, those making decisions regarding activation of a clinical trial, such as researchers, clinical research operations staff, and administrators, require reliable and unbiased information regarding the probable trial performance. Our analyses suggest that this model succeeds in that regard.
There are limitations to this study. This methodology has only been tested at a single center. We are presently performing similar analyses at other centers to assess reproducibility. Even if the parameters are generally applicable, models will likely require local calibration. Additionally, this model relies on secondary data. Thus, model quality is highly dependent on data quality in both the CTMS and ClinicalTrials.gov. Also, being a secondary research project, some variables that may affect accrual were either not available to us or unknown, such as types of interventions, route of administration, and other study characteristics. Over time, the model will require recalibration because of changes in the local clinical trial landscape, such as the addition of new practitioners to a team This work builds on the current literature in that it provides a methodology to determine accrual at a single site before study activation, a process not previously defined. This model meets the criteria for use laid out by Barnard et al 12 in that it (1) is simple to use and understand; (2) can adapt to epidemiologic changes; (3) can adapt to environmental changes; (4) is able to take account of center recruitment, and; (5) is able to inform commissioning decisions. This analysis was not intended to provide an "autopilot" for determining which studies to activate, because scientific merit of a trial was not considered. It is simply intended to provide a quantitative means for yielding unbiased accrual estimates for proposed clinical trials at a given center. We designed this analysis to employ easily available, concrete, realworld data points that, after model calibration, could be quickly and easily used by decision-makers. Our model, when considered holistically, can inform decision-makers regarding intelligent allocation of scarce resources. 
Conclusions
We identified and validated key factors, both nationally and locally, associated with subject accrual to treatment and supportive care interventional clinical trials at one site. This model generates an accurate, quick, and valuable metric in assessing potential trial accrual. Further research includes national expansion of the model to cancer centers to validate this methodology in quantitatively assessing clinical trial feasibility.
